星期四 - 3月 22, 2018

交易預計在2018年第二季完成

歐盟有條件核准拜耳收購孟山都

       勒沃庫森訊,2018年3月21日─歐盟在3月21日有條件核准拜耳收購孟山都的交易案。「歐盟的核准是重要的成功,更是重大的里程碑。」拜耳總裁Werner Baumann表示,「拜耳和孟山都攜手,希望幫助全世界的農民以更永續的方式種植更多營養的農作物,嘉惠消費者和環境。」30多個審查機關中,拜耳已經獲得超過一半的核准,包括巴西和中國。

       歐盟核准的條件涵蓋拜耳特定業務的剝離,包括全球大田作物種子業務,如芥花、棉花和大豆,但在亞洲地區會有少數例外。也包括雜交小麥種子的研發平台,全球蔬菜種子業務,全球固殺草除草劑業務,還有一些主要為工業用途的歐洲嘉磷塞除草劑業務。此外,孟山都全球的殺線蟲劑NemaSrike也必須剝離。這些條件還明定拜耳必須轉移三項非選擇性的除草劑研發計畫和數位農業產品組合的許可證。巴斯夫有意買下這些資產。

       交易案仍需符合特別成交條件,包括獲得審查機關的核准。拜耳和孟山都將全力配合審查機關,其中也包括美國司法部,以2018年第二季完成交易為目標。

關於拜耳

       拜耳是一間核心競爭力在於醫療保健與農業領域的全球性生命科學企業。我們提供專為造福人群與提升生活品質而設計的產品與服務。集團更以創新、成長與高獲利力來創造價值作為目標。拜耳致力於遵守永續發展的原則,並負起作為企業公民的社會與倫理責任。在2017財務年度中,集團旗下共有約99,800位員工,營業額為350億歐元。資本支出達24億歐元,研發支出為45億歐元。更多資料,請至www.bayer.com.tw

 

Forward-Looking Statements

Certain statements contained in this communication may constitute “forward-looking statements.” Actual results could differ materially from those projected or forecast in the forward-looking statements. The factors that could cause actual results to differ materially include the following: uncertainties as to the timing of the transaction; the possibility that the parties may be unable to achieve expected synergies and operating efficiencies in the merger within the expected time-frames or at all and to successfully integrate Monsanto’s operations into those of Bayer; such integration may be more difficult, time-consuming or costly than expected; revenues following the transaction may be lower than expected; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) may be greater than expected following the announcement of the transaction; the retention of certain key employees at Monsanto; risks associated with the disruption of management’s attention from ongoing business operations due to the transaction; the conditions to the completion of the transaction may not be satisfied, or the regulatory approvals required for the transaction may not be obtained on the terms expected or on the anticipated schedule; the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the merger; the impact of the refinancing of the loans taken out for the transaction, the impact of indebtedness incurred by Bayer in connection with the transaction and the potential impact on the rating of indebtedness of Bayer; the effects of the business combination of Bayer and Monsanto, including the combined company’s future financial condition, operating results, strategy and plans; other factors detailed in Monsanto’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended Thursday, August 31, 2017 and Monsanto’s other filings with the SEC, which are available at http://www.sec.gov and on Monsanto’s website at www.monsanto.com; and other factors discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. Bayer and Monsanto assume no obligation to update the information in this communication, except as otherwise required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.